BACKGROUND: With the progress of surgical techniques and devices, laparoscopic hepatectomy (Lap-Hx) became a realizable option for patients with liver tumors. However, the feasibility of Lap-Hx for metastatic liver tumor of colorectal cancer also should be guaranteed oncologically. This study evaluated the short- and long-term outcomes of Lap-Hx compared with open hepatectomy (Open-Hx) for patients with colorectal liver metastasis (CLM) by matched-pair analysis. METHODS: This study enrolled 21 patients who underwent Lap-Hx and compared them with 21 matched patients who underwent Open-Hx. The following parameters were matched between the two cohorts: tumor size, tumor location, and operative procedures. Both short- and long-term outcomes of Lap-Hx were compared with those of Open-Hx. RESULTS: No difference was observed between the two groups in terms of age, gender, tumor size, or operative procedures. With regard to short-term outcomes, the operative time for Lap-Hx (377 ± 29 min) was similar to that for Open-Hx (369 ± 31 min), whereas the blood loss for the patients who underwent a Lap-Hx (198 ± 39 ml) was significantly less than for those who underwent an Open-Hx (326 ± 50 ml). The incidence of postoperative complications among the patients who underwent Lap-Hx tended to be lower than for the patients who underwent Open-Hx, and intraabdominal abscess was observed only in the Open-Hx group. The hospital stay for Lap-Hx (average, 18.3 days) tended to be shorter than for Open-Hx (27 days). With respect to long-term outcomes, the two groups did not differ significantly in terms of 5-year overall and disease-free survival rates. CONCLUSIONS: Lap-Hx is a safe and feasible option for selected patients with CLM. The short- and long-term outcomes of Lap-Hx also are considered to be acceptable.
BACKGROUND: With the progress of surgical techniques and devices, laparoscopic hepatectomy (Lap-Hx) became a realizable option for patients with liver tumors. However, the feasibility of Lap-Hx for metastatic liver tumor of colorectal cancer also should be guaranteed oncologically. This study evaluated the short- and long-term outcomes of Lap-Hx compared with open hepatectomy (Open-Hx) for patients with colorectal liver metastasis (CLM) by matched-pair analysis. METHODS: This study enrolled 21 patients who underwent Lap-Hx and compared them with 21 matched patients who underwent Open-Hx. The following parameters were matched between the two cohorts: tumor size, tumor location, and operative procedures. Both short- and long-term outcomes of Lap-Hx were compared with those of Open-Hx. RESULTS: No difference was observed between the two groups in terms of age, gender, tumor size, or operative procedures. With regard to short-term outcomes, the operative time for Lap-Hx (377 ± 29 min) was similar to that for Open-Hx (369 ± 31 min), whereas the blood loss for the patients who underwent a Lap-Hx (198 ± 39 ml) was significantly less than for those who underwent an Open-Hx (326 ± 50 ml). The incidence of postoperative complications among the patients who underwent Lap-Hx tended to be lower than for the patients who underwent Open-Hx, and intraabdominal abscess was observed only in the Open-Hx group. The hospital stay for Lap-Hx (average, 18.3 days) tended to be shorter than for Open-Hx (27 days). With respect to long-term outcomes, the two groups did not differ significantly in terms of 5-year overall and disease-free survival rates. CONCLUSIONS:Lap-Hx is a safe and feasible option for selected patients with CLM. The short- and long-term outcomes of Lap-Hx also are considered to be acceptable.
Authors: Eddie K Abdalla; René Adam; Anton J Bilchik; Daniel Jaeck; Jean-Nicolas Vauthey; David Mahvi Journal: Ann Surg Oncol Date: 2006-09-06 Impact factor: 5.344
Authors: Alfredo D Guerron; Shamil Aliyev; Orhan Agcaoglu; Erol Aksoy; Halit Eren Taskin; Federico Aucejo; Charles Miller; John Fung; Eren Berber Journal: Surg Endosc Date: 2012-10-10 Impact factor: 4.584
Authors: S Truant; A F Bouras; M Hebbar; E Boleslawski; G Fromont; S Dharancy; E Leteurtre; P Zerbib; F R Pruvot Journal: Surg Endosc Date: 2011-06-18 Impact factor: 4.584
Authors: Joseph F Buell; Mark T Thomas; Steven Rudich; Michael Marvin; Ravi Nagubandi; Kadiyala V Ravindra; Guy Brock; Kelly M McMasters Journal: Ann Surg Date: 2008-09 Impact factor: 12.969
Authors: Michael Tsinberg; Gurkan Tellioglu; Conrad H Simpfendorfer; R M Walsh; Matthew R Walsh; David Vogt; John Fung; Eren Berber Journal: Surg Endosc Date: 2008-12-31 Impact factor: 4.584
Authors: Kevin Tri Nguyen; Alexis Laurent; Ibrahim Dagher; David A Geller; Jennifer Steel; Mark T Thomas; Michael Marvin; Kadiyala V Ravindra; Alejandro Mejia; Panagiotis Lainas; Dominique Franco; Daniel Cherqui; Joseph F Buell; T Clark Gamblin Journal: Ann Surg Date: 2009-11 Impact factor: 12.969
Authors: Juan C Rodríguez-Sanjuán; Marcos Gómez-Ruiz; Soledad Trugeda-Carrera; Carlos Manuel-Palazuelos; Antonio López-Useros; Manuel Gómez-Fleitas Journal: World J Gastroenterol Date: 2016-02-14 Impact factor: 5.742